← Back to Clinical Trials
Recruiting NCT04617717

NCT04617717 Personalized Treatment for Patients With Premature Ventricular Beats

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04617717
Status Recruiting
Phase
Sponsor Oslo University Hospital
Condition Ventricular Premature Complexes
Study Type OBSERVATIONAL
Enrollment 224 participants
Start Date 2020-09-30
Primary Completion 2024-06-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 90 Years
Study Type OBSERVATIONAL
Interventions
Invasive cardiac electrophysiological study and ablation therapyCardiopulmonary exercise testingCardiac MRI

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 224 participants in total. It began in 2020-09-30 with a primary completion date of 2024-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Frequent premature ventricular beats (PVBs) are common, negatively affects the quality of life for many patients, and can lead to impaired contractile function. Rule-out of structural heart disease is key in the assessment of PVBs. Cardiac MR has a high sensitivity for structural heart disease, but the diagnostic gain from this resource-demanding procedure in the work-up of patients with PVBs is unknown. There is a need to establish the role of MR in the evaluation of patients with PVBs to improve diagnostic efficacy, establish treatment strategies, and promote further research. This project will answer three key questions: 1) What is the diagnostic gain from cardiac MR in patients with PVBs? 2) Is MR the real gold standard to rule-out structural heart disease in patients with PVBs? 3) Can non-invasive heart rate parameters guide the strategy for induction of PVBs during invasive electrophysiological procedures?

Eligibility Criteria

Inclusion Criteria: Patients referred for PVC ablation

Contact & Investigator

Central Contact

Mathis K Stokke, MD PhD

✉ m.k.stokke@medisin.uio.no

📞 90696883

Principal Investigator

Mathis K Stokke, MD PhD

PRINCIPAL INVESTIGATOR

Oslo University Hospital

Frequently Asked Questions

Who can join the NCT04617717 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Ventricular Premature Complexes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04617717 currently recruiting?

Yes, NCT04617717 is actively recruiting participants. Contact the research team at m.k.stokke@medisin.uio.no for enrollment information.

Where is the NCT04617717 trial being conducted?

This trial is being conducted at Oslo, Norway.

Who is sponsoring the NCT04617717 clinical trial?

NCT04617717 is sponsored by Oslo University Hospital. The principal investigator is Mathis K Stokke, MD PhD at Oslo University Hospital. The trial plans to enroll 224 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology